Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial presented at the 2021 ASCO Annual Meeting. The study is a prospective, randomized, open-label, multicenter, crossover, trial that assessed patient preference between darolutamide (Nubeqa) and enzalutamide (Xtandi) in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer. Shore is medical director of the Carolina Urologic Research Center.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.